ArticleBiomedicines2026

Long-Term Comparative Outcomes of TNF-α Antagonists vs. Vedolizumab as First-Line Biologic Therapy for Refractory Ulcerative Proctitis: A Propensity-Matched Study.

Ayushi Shah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.